Inhalation Capsules Market Analysis

Type (Gelatin Capsules, Hypromellose Capsules)

The gelatin capsules sub-segment emerged as the largest segment in the inhalation capsules market in 2022. It is still the biggest shareholder in the market and accounts for 59% of the total global revenue. Gelatin capsules enable more accurate distribution of the medication so that the patient gets the right amount of drug per inhalation. This precision is important in respiratory medicine because many of the drugs used in the specialty have a narrow therapeutic index, and proper dosing requirements are crucial in achieving the optimal therapeutic effect without causing toxicity. For dry powder inhalers to deliver active pharmaceutical ingredients into the lungs, hypromellose (HPMC) is purely of plant origin and does not contain any animal-derived material. These capsules are less likely to produce fragments when the inhaler needle punctures them in comparison to gelatin capsules. The remaining particles on the capsule wall are relatively less, and they are less dependent on the mechanical strength of air humidity. They are also suitable for hygroscopic APIs. It is listed on Drug Master Files for the US and Canada and CDE in China and produced in a well-validated production line that meets GMP standards. Coming back to our largest shareholder, the gelatin capsule market is an industry worth a whopping 43.7 million, as accounted last in 2020.

Application (Asthma Treatment, COPD Management, and Others)

The Asthma treatment segment is by far the largest sub-segmentation in the application of inhalation capsules market. North America leads the global asthma treatment market with a share of 41.66%, which was last accounted for in 2023. The global inhalation capsules market is also categorized into segments of asthma treatment, COPD treatment, and others. The inhalation capsules are very convenient as they are rapid and easy to administer; hence, they are suitable for use in case of a severe asthma attack. Inhalers are convenient in that they are portable and can be used by the patient themselves as and when required, thus providing the patient with some control over the illness. Targeted administration to the lungs is safe and effective because it avoids systemic side effects while treating inflammation and bronchoconstriction in the respiratory system. Inhalation pills are highly effective in managing long-term asthma issues such as persistent airway obstruction. Both COPD and asthma can be treated through the use of inhaled drugs, and Corticosteroids and Bronchodilators can be delivered using inhalation capsules as well as combination therapy. This versatility helps healthcare practitioners to develop a treatment plan for patients based on individual parameters such as the severity of the condition, other diseases, and sensitivity to certain medications. inhalation capsules or DPIs have also been associated with a pulmonary drug deposition rate that can be as high as 40% of the administered dose, provided patients use optimally controlled inhalation flows through the device. Otherwise, lung deposition can be as low as ~15%.

Our in-depth analysis of the global inhalation capsules market includes the following segments: